Curi Bio, a Seattle, WA-based developer of human iPSC-based platforms for drug discovery, acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays.
The amount of the deal was not disclosed.
Through the acquisition, Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn™, a deep learning platform for modeling cell and tissue phenotypes; Pulse™, an automated platform for contractility analysis of beating cardiomyocytes; and PhenoTox™, a patented deep learning platform for predictive safety pharmacology.
With the acquisition, Curi is now positioned to offer pharma companies an integrated platform leveraging predictive human iPSC-derived cells, tissue-specific biosystems, and AI/ML-enabled phenotypic data insights.
Led by CEO Michael Cho, Curi provides human iPSC-based platforms that help drug developers build predictive and mature human iPSC tissues—especially for the discovery, safety testing, and efficacy testing of new therapeutics—with a focus on cardiac, skeletal muscle, and neuromuscular disease models.
Through a collaboration with the Health and Environmental Sciences Institute (HESI), Dana has previously received funding from the Food and Drug Administration (FDA) to validate PhenoTox™ for the predictive assessment of drug-induced structural cardiac toxicity. Curi and Dana will continue the FDA project following the acquisition. Dana’s SaaS platforms will continue to operate until the expiration of existing customer contracts.